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Follow-up to genome-wide linkage
and admixture mapping studies
implicates components of the
extracellular matrix in susceptibility
to and size of uterine ﬁbroids
Brahim Aissani, Ph.D.,a Kui Zhang, Ph.D.,b and Howard Wiener, Ph.D.a
a Department of Epidemiology and b Department of Biostatistics, University of Alabama at Birmingham, Birmingham,
AlabamaObjective: To conduct a follow-up association mapping to independent genome-wide linkage and admixture mapping studies of
uterine leiomyoma.
Design: Case-control, cross-sectional study.
Setting: Not applicable.
Patient(s): A total of 1,045 premenopausal North American participants in the National Institute of Environmental Health Sciences
Uterine Fibroid Study.
Intervention(s): None.
Main Outcome Measure(s): We genotyped 2,772 single-nucleotide polymorphisms from candidate genes located in peaks of linkage
(2q37, 3p21, 5p13, 10p11, 11p15, 12q14, and 17q25) or admixture linkage disequilibrium (2q37, 4p16.1, and 10q26) mapping and
reported to have regulated expression in uterine ﬁbroids.
Result(s): We report signiﬁcant associations of variant members of the collagen gene family with risk and tumor size, including
missense variants in COL6A3 and COL13A, with replications in African American and European American study groups. Furthermore,
the cell-matrix Rho GTPase-encoding ARHGAP26 gene, and MAN1C1, a gene encoding a Golgi mannosidase involved in the
maturation of procollagens, emerged as new candidate uterine leiomyoma genes affecting both risk and tumor size.Use your smartphoneConclusion(s): Our data converge onto a possible model of uterine leiomyoma pathogenesis
resulting from altered regulation, maintenance, and/or renewal of the extracellular matrix. (Fer-
til Steril 2015;103:528–34. 2015 by American Society for Reproductive Medicine.)
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including excessive bleeding, pelvic
pain, urinary incontinence, infertility,
and pregnancy complications (2,
3). As a consequence of this
morbidity, uterine ﬁbroids are the
primary indication for hysterectomy,
accounting for over 600,000
hysterectomies annually in the United
States (4). Cumulative exposure to
estrogen is believed to be a major
etiologic factor (5), and factors that
may inﬂuence the hormonal milieu,
such as obesity, are also believed to beVOL. 103 NO. 2 / FEBRUARY 2015
Fertility and Sterility®associated with the risk (6). However, the clearly established
risk factors are age (increasing risk with increasing
premenopausal age), menopause (risk decreases with
menopause), and African American ethnicity (higher risk
compared with that of non-Hispanic whites) (7).
No candidate susceptibility genes have consistently
emerged from the few linkage scans and genome-wide asso-
ciation studies reported so far (8–11). Exome sequencing in 18
UL tumors andmatched normal myometria has implicated the
mediator complex subunit 12 (MED12) gene (12). Further
examinations of exomes and gene-expression proﬁling in a
set of 38 ULs and matched myometria led to the hypothesis
that a chromothripsis-like event drives the pathogenesis of
ULs, leading to translocations of the HMGA2 and RAD51B
loci and to other chromosomal aberrations, including the
COL4A5-COL4A6 locus (13).
In contrast to these somatic mutations, germline muta-
tions affecting highly conserved amino acids have been re-
ported for the fumarate hydratase–encoding gene (FH) in
band q43 on chromosome 1, but only in rare cases of nonsyn-
dromic ULs (14, 15). Furthermore, a genome-wide linkage
scan in the ‘‘affected sister study’’ (8), and ﬁne association
mapping across the FH-linked region in the National Institute
of Environmental Health Sciences (NIEHS) cohort (16), sug-
gested the presence of a candidate 1q43 gene affecting the
risk and size of ULs. More recently, epidemiologic studies of
ULs in American women enrolled in the Right from the Start
cohort, and the BioVU DNA repository, replicated the results
of a genome-wide association study in a Japanese population
for 2 of the 3 most signiﬁcantly associated genes encoding
BET1L (blocked early in transport 1 homolog) and TNRC6B
(trinucleotide repeat containing 6B) (17, 18).
We conducted an independent follow-up ﬁne mapping
of extended candidate regions that were identiﬁed in a
genome-wide linkage scan in the affected sister study (11)
and through mapping by admixture linkage disequilibrium
(MALD) in the Black Women's Health Study (10). We report
data from both the African American (AA) and European
American (EA) study groups showing association of UL out-
comes with variant members of the collagen gene family en-
coding components of the extracellular matrix suspected in
ﬁbrosis (19).MATERIALS AND METHODS
Study Population
Detailed characteristics of the study population have been re-
ported elsewhere (20); only those relevant to the present study
are described here. A random sample of women, aged 35 to
51 years, was selected from a computerized list of members
of a prepaid urban health plan for enrollment in the NIEHS
Uterine Fibroid Study (NIEHS-UFS) (7). Of the enrolled
women who were premenopausal and had a diagnosis of UL
(n ¼ 1,119), 1,045 (93%) had available DNA specimens and
were self-identiﬁed as AA (n ¼ 574), non-Hispanic EA (n ¼
394), and Other (O; n ¼ 77). The NIEHS-UFS and the present
substudy were approved by the human subjects review boards
at the NIEHS, GeorgeWashington University, and the Univer-
sity of Alabama at Birmingham, respectively. ParticipantsVOL. 103 NO. 2 / FEBRUARY 2015gave written informed consent in accordance with the re-
quirements of these review boards.Covariates and Ascertainment
The covariates included age, age at menarche, parity, number
of pregnancies after age 25 years (giving birth at younger ages
was not signiﬁcantly related to ﬁbroid development in the
NIEHS-UFS [21, 22]), body mass index, and physical
activity. Fibroid status was assessed by ultrasound
screening at baseline or by medical record review in 80%
and 90% of the AA and EA participants, respectively. For
women who had a pelvic ultrasound examination recently
through the health plan, radiology records from that
examination were used to assess ﬁbroid status. The
remaining premenopausal participants were asked to have a
pelvic ultrasound examination at the primary care site.
Women for whom neither ultrasound nor medical record
review could be conducted were excluded from the analyses.
Both a transabdominal and a transvaginal ultrasound ex-
amination were performed. The abdominal portion evaluated
ﬁbroid change arising from the upper uterus that would not be
seen readily with the transvaginal approach alone. Tumor size
was classiﬁed into 3 categories, according to tumor diameter
(small:%2 cm; medium:>2–<4 cm; large:R4 cm). For par-
ticipants diagnosed with multiple tumors, the largest tumor
determined the size category.Target Positional Candidate Regions and Genes
Genes identiﬁed as being in extended peaks of linkage (2q37,
3p21, 5p13, 10p11, 11p15, 12q14, and 17q25) with ULs, in the
affected sister study (11), and of admixture linkage disequilib-
rium (2q37, 4p16.1, 10q26), in the Black Women's Health
Study (10), were selected on the basis of regulated expression
(down- or up-regulated) in ULs. The criterion for inclusion
was a differential expression (P< .01) in 5 pairs of ﬁbroids
and matched myometria in at least 2 independent studies re-
ported in the GeoProﬁle database (National Center for
Biotechnology Information). Overall, this strategy identiﬁed
93 positional, and 4 nonpositional, candidate genes. In addi-
tion, we included 3 positional genes (CYP27B1, PRLHR, and
HMGA2) that were not reported in the Geoproﬁle database as
being strongly regulated in ULs but are considered strong
candidates.Single-Nucleotide Polymorphism Selection and
Typing
Within the selected candidate genes, tagging single-
nucleotide polymorphisms (tag SNPs) were selected from
the International HapMap Project (HapMap) reference popu-
lations (www.hapmap.org), as described elsewhere (23).
Because the participants in the NIEHS-UFS are predominantly
of AA or EA descent, we downloaded SNP genotype data from
the reference HapMap II and III populations relevant to these
ethnic backgrounds and used the NIEHS TAGster (24) to select
tag SNPs, as described elsewhere (16). We selected 537 tag
SNPs for the top 15 candidate positional genes, and 652
SNPs for the remaining 85 positional candidates. The top 15529
ORIGINAL ARTICLE: GYNECOLOGY AND MENOPAUSEcandidates included CYP27B1, PRLHR, HMGA2, and 12
other genes suspected in the pathogenesis of ULs. To this set
of 1,189 tag SNPs, we added 1,583 SNPs selected for a sepa-
rate MALD study. In selecting SNPs from the reported set of
3,011 MALD SNPs across the human genome (25), we gave
priority to those that overlapped the peaks of linkage, in the
affected sister study, and of admixture linkage disequilibrium,
in the Black Women's Health Study. This yielded a ﬁnal set of
2,772 interpopulation tag SNPs. The Illumina iSelect assay (Il-
lumina Inc.) was used to type the selected SNPs at the Hudson
Alpha Institute for Biotechnology in Huntsville, AL. Reli-
ability in the typing data was assessed by inclusion of blind
intra- and inter-plate duplicates representative of each of
the study population groups.Statistical Analysis
Quality control. SNP calls were checked for deviation from
Hardy-Weinberg equilibrium in each of the affection status
and population strata, and only SNPs showing no signiﬁcant
deviation (P< .01) in UL-free controls were included for ana-
lyses (Supplemental Material). Potential inﬂations of the test
statistics were evaluated in quantile-quantile plots within
each population stratum.
Analytical design. Association of SNP variants with the risk
and size of ULs was evaluated separately in each population
stratumusing dichotomous and polytomous logistic regression
modeling inSAS (SAS,Cary,NC), respectively,with adjustment
for covariates. For the polytomous models, only the SNP tests
that met the assumption for proportional odds are reported.
Principal component analysis–based race groups were
determined by discriminant analysis of an extended set
of 4,363 SNPs in a previous study (16). Early studies in NIEHS-
UFS have assessed the levels of the ordinal covariates that inﬂu-
enced or modiﬁed the risk of ULs (20, 22, 26); we therefore
modeled these covariates accordingly. Speciﬁcally, we
modeled age as a continuous variable and body mass index as
an ordinal variable (based on categories <25, 25–<30, 30–
<35, >35). The other covariates were age of menarche
modeled as a dichotomous variable (age %11 years vs. other
ages), exercise as a 4-level ordinal variable (lower third, middle
third, next sixth, top sixth, as described elsewhere [20]), and par-
ity, deﬁned ashavingornot havinggivenbirth at ageR25years
(binary variable), as these were the only pregnancies shown to
have protective effects in the NIEHS-UFS (22).
Multivariate-adjusted odds of UL associated with marker
genotypes in PCA-deﬁned race groups were estimated by lo-
gistic regression using a 2-df test. UL was modeled as a
dichotomous outcome (case-control design) or as a polyto-
mous outcome across UL size categories—none, small, me-
dium, and large. As the present study is a follow-up of
positional candidate regions, correction for multiple testing
was not based on the total SNP tests but on each series of tests
within individual candidate regions. We report 2-sided P
values (or Log10 P value) of the tests of signiﬁcance for
the association of the ULs and tumor size outcomes with
main effects of SNP genotypes, separately, in the 2 predomi-
nant AA and EA ethnic groups.530RESULTS
The characteristics of the participants available for the study
were described in a previous report (16). Several covariates
showed different distributions between the 2 major ethnic
groups, outlining the necessity of conducting separate ana-
lyses. Compared with most UL studies, UL-free controls
were clinically ascertained (by ultrasound screening) in
NIEHS-UFS, thus limiting the rate of misclassiﬁcation. After
quality-control ﬁltering (Supplemental Material available on-
line), there were 525 AA, 391 EA, and 70 Other-category in-
dividuals available for analysis.
Of the 2,772 SNPs selected for typing, 288 (10.3%) were
excluded because the assay failed or the SNP was monomor-
phic or rare; the yield available for analyses was 1,070 posi-
tional SNPs and 1,414 MALD SNPs. A large number of the
selected MALD SNPs are also positional markers, as those
located in the linkage and admixture peaks were prioritized
in the selection process. The 2 SNP selections differ in that
the tag SNPs were selected within positional genes whose
expression is regulated (up- or down-regulation) in ULs,
whereas the MALD SNPs were randomly selected within the
candidate chromosomal regions. Because of this difference
in selection, the study results are reported separately for these
2 sets of SNPs.
Supplemental Figures. 1–8 show the quantile-quantile
plots of the P values from race-stratiﬁed and multivariate-
adjusted models for risk and tumor size, separately for the
MALD (Supplemental Figures 1, 2, 5, and 6) and non-MALD
SNPs (Supplemental Figures 3, 4, 7, and 8). No appreciable
inﬂation of the test statistics was observed; however, deﬂa-
tion, indicating fewer than expected low P values, was
observed in several models. The deﬂation may be explained
by loss of statistical power at SNPs that exhibit low minor-
allele frequency in one study population but are common in
the other.
The results showed comparable association patterns
between these 2 sets of SNPs and the risk of ULs; signiﬁcant
associations (P< .05) were found on chromosomes 4p16,
10q26, and 11p15, for both sets of SNPs (Supplemental
Figs. 9 and 10, available online), and additionally on chromo-
somes 1p35, 1q23, and 12q for theMALD SNPs (Supplemental
Fig. 10). The association with tumor size outcome highlighted
the same candidate regions, namely the 10q22-26 and 11p15
genomic regions (Supplemental Fig. 11, available online),
and most notably, chromosome 1p35 in the AA population,
and chromosome 5q31 in EAs for the MALD SNPs
(Supplemental Fig. 12, available online).
The results for the most statistically signiﬁcant (P< .01)
positional SNPs for the risk and tumor size outcomes are sum-
marized in Table 1. The data show that among the regulated
genes in ﬁbroid tumors, 2 members of the collagen gene fam-
ily, COL6A3 on 2q37 and COL13A1 on 10q22, are associated
with both risk and tumor size in the EA study population, with
the results replicated in the AA population at similar signiﬁ-
cance levels (P< .01) for COL13A1, and at moderate signiﬁ-
cance levels (.01<P< .05) for the positional COL6A3 gene
(Supplemental Table 1, available online). The intronic SNP
rs3793825 in COL13A1 showed the strongest association inVOL. 103 NO. 2 / FEBRUARY 2015
TABLE 1
List of top positional candidate genes for uterine ﬁbroids identiﬁed in the NIEHS Uterine Fibroid Study cohort using a selected set of single-
nucleotide polymorphisms.
SNP Chr. band Position, bp Gene
Adjusted P values
EA AA
Risk Tumor size Risk Tumor size
rs2646262 2q37 238,258,280 COL6A3 .020 .007 – –
rs1553032 2q37 238,305,211 COL6A3 .027 .005 – –
rs6808142 3p21 46,556,835 LRRC2 – – .002 .041
rs17296973 3p21 46,595,431 LRRC2 na na – .003
rs2280408 3p21 46,599,457 LRRC2 .009 .001 – –
rs17427485 3p21 38,569,857 LIFR .038 .001 – –
rs10040852 5p13 38,580,741 LIFR .039 .0008 – –
rs10512687 5p13 38,581,262 LIFR .046 .001 – –
rs4746912 10q22 71,564,996 COL13A1 .008 .007 – –
rs2763357 10q22 71,573,082 COL13A1 .009 .005 – .034
rs12777790 10q22 71,584,149 COL13A1 – – – .005
rs1227739 10q22 71,618,311 COL13A1 – – .026 .066
rs3793832 10q22 71,672,879 COL13A1 .007 .002 – –
rs1227779 10q22 71,687,211 COL13A1 .004 .002 – –
rs3793825 10q22 71,687,492 COL13A1 .001 .0009 – –
rs2637229 10q22 71,689,148 COL13A1 .005 .001 .091 –
rs2683571 10q22 71,690,475 COL13A1 .006 .004 – –
rs7924316 11p15 2,173,447 INS-IGF2 .004 .025 – –
rs3842748 11p15 2,181,395 INS .009 .082 – –
Note: All SNPs are located in introns, except for rs6808142, which maps to the immediate downstream region of LRRC2 (leucine rich repeat containing 2 gene). P values are adjusted for the effects
of age, age at menarche, parity, body mass index, and physical activity. Only SNPs with a P value of< .01 in at least one of the race strata or outcomes are shown. Except for COL13A1, all the listed
genes map within peaks of linkage (2q37, 3p21, and 11p15), in the affected sister study (11), or admixture linkage disequilibrium, in the Black Women's Health Study (10) for uterine ﬁbroids. The
symbol (–) indicates not signiﬁcant at the signiﬁcance level of .05; na indicates monomorphic SNP in the tested study population. bp¼ base pair; Chr.¼ chromosomal; COL6A3¼ collagen, type VI,
alpha 3-encoding gene; COL13A1¼ collagen, type XIII, alpha 1 gene; INS-IGF2¼ Insulin-insulin-like growth factor 2 readthrough; LIFR¼ leukemia inhibitory factor receptor alpha-encoding gene;
LRRC2 ¼ leucine rich repeat containing 2 gene.
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comes, respectively). These ﬁndings were further substanti-
ated by observed mutations affecting the risk and/or size of
ULs. These mutations are located in COL6A3 c.9034G>C
(p.Ala3012Pro) at rs2270669 (P¼ .031 and P¼ .018 for risk
and tumor size, respectively) in the EA group; in c.6653C>T
(p.Pro2218Leu) at rs36117715 (P¼ .029 for the size of ULs)
in the AA group; and in COL13A1 c.784G>A (p.Glu262Lys)
at rs41277962 (P¼ .044 for risk) in the EA group
(Supplemental Table 1).
Positional INS (the insulin gene) and IFG2 (the insulin
growth factor 2 gene), 2 regulated and suspected genes in
ULs, show signiﬁcant associations with risk and tumor size in
the EA population, and a marginal association (P¼ .06) at the
IGF2 SNP rs3213216 in the AA population (Supplemental
Table 1). Two unsuspected positional genes, LRRC2 (leucine-
rich repeat containing 2) on 3p21 and LIFR (leukemia inhibi-
tory factor receptor alpha) on 5p13 were also highlighted as
potential candidates in both study populations, showing the
highest level of statistical signiﬁcance for tumor size
(P¼ .0008), at the LIFR SNP rs10040852, in the EA population.
The tests with the MALD SNPs highlighted several associ-
ated genes located within or closer to the candidate chromo-
somal regions, but these genes were different from those
identiﬁed with the positional SNPs (Table 2). The 2 most
signiﬁcantly associated genes identiﬁed through MALD SNP
testing are located outside the candidate chromosomal re-
gions. They were tagged in the AA population by rs3014712
(P¼ .001 and P¼ .0001 for the risk and tumor size outcomes,VOL. 103 NO. 2 / FEBRUARY 2015respectively) in MAN1C1 (mannosidase, alpha, class 1C,
member 1-encoding gene), and in the EA population by
rs35294 (P¼ .014 and P¼ .0006 for the risk and tumor size
outcomes, respectively) in ARHGAP26 (Rho GTPase acti-
vating protein 26-encoding gene). As can be predicted by
the large inter-MALD SNP spacing (on average 1 SNP/
1 Mb), only a few SNP associations were replicated in either
study population (Supplemental Table 2, available online).
Overall, this study identiﬁed 146 SNPs within at least 29
positional genes (Supplemental Table 1), and 178MALD SNPs
within at least 119 genes (Supplemental Table 2) that passed
the multiple testing–uncorrected signiﬁcance threshold of
.05 in either outcome or study population. After correction
for multiple testing, none of the signiﬁcant positional SNPs
passed the Bonferroni-corrected signiﬁcance thresholds,
which were .0003 for 2q37 SNPs, .0004 for 3p21 SNPs,
.0003 for 5p13 SNPs, and .0009 for 11p15 SNPs. However,
the most signiﬁcant SNPs have P values close to the
Bonferroni-corrected thresholds. Likewise, no MALD SNPs
passed the Bonferroni-corrected threshold of .00004, but the
2 most signiﬁcant SNPs, rs3014712 in MAN1C1 (P¼ .0001)
and rs35294 in ARHGAP26 (P¼ .0006) have P values close
to the Bonferroni-corrected threshold.DISCUSSION
We report new data on the genetic basis of susceptibility to
and size of uterine ﬁbroids, implicating for the ﬁrst time en-
coded components of the extracellular matrix, which are531
TABLE 2
List of top positional and nonpositional candidate genes for uterine ﬁbroids identiﬁed in the NIEHS Uterine Fibroid Study cohort using a random
set of single-nucleotide polymorphisms.
SNP Chr. band Position, bp Gene
Adjusted P values
EA AA
Risk Tumor size Risk Tumor size
rs6603855 1p36 16,460,541 EPHA2 .059 .009 – –
rs3014712 1p35 25,991,356 MAN1C1 – – .001 .0001
rs12737539 1q23.3 162,198,429 NOS1AP .001 .003 – –
rs520354 2p24 21,259,612 APOB – – – .004
rs1402467 2q12.3 108,994,808 SULT1C4 .022 .004 – –
rs35619282 4p15.3 15,051,602 CPEB2 .007 .025 – –
rs35294 5q31 142,359,037 ARHGAP26 .014 .0006 – –
rs1159006 10q23 100,406,283 HPSE2 – – .009 .032
rs1953638 10q23 100,466,685 HPSE2 – – .004 .006
rs4595478 10q25.2 111,800,145 ADD3 – – .008 –
rs2076974 10q25.2 111,820,311 ADD3 – – .008 –
rs2071095 11p15.5 2,020,627 H19 .019 .003 – –
rs7933164 11p15.5 4,093,950 STIM1 .003 .005 – –
rs766498 11p15.4 7,257,474 – .009 – .055
rs1223079 11p13 31,456,846 IMMP1L .061 – – .008
rs2755168 11p13 34,289,241 ABTB2 – .010 – –
rs590274 11q21 95,715,570 MAML2 .003 .010 – –
rs593226 12q24.1 111,993,886 ATXN2 .018 .008 – .048
rs2270788 12q24 123,414,349 ABCB9 – – .008 .050
Note: All SNPs are intronic, except for the intergenic SNP rs766498; the nonsynonymous SNP rs1402467 at the coding position c.15C>G (p.Asp5Glu) of SULT1C4; the 50 UTR SNP rs2071095 in the
non–protein codingH19 gene; and the 30 UTR SNP rs2270788 inABCB9. P values are adjusted for the effects of age, age atmenarche, parity, bodymass index, and physical activity. Only SNPs with a
P value of< .01 in at least one of the race strata or outcomes are shown. The MALD SNPs in 11p15 are positional SNPs located in one of the linkage peaks for uterine ﬁbroids in the affected sister
study (11). (–) indicates not signiﬁcant at the signiﬁcance level of .05. ABCB9¼ATP-binding cassette, subfamily B (MDR/TAP) encoding gene; ATP¼ adenosine triphosphate; bp¼ base pair; Chr.¼
chromosomal; H19¼ imprinted maternally expressed transcript; MDR¼multidrug resistance; SULT1C4¼ sulfotransferase family, cytosolic, 1C, member 4 gene; TAP¼ transporter associated with
antigen processing; UTR ¼ untranslated region.
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follow-up of candidate regions in the NIEHS-UFS, coupled
with the screening of positional genes with regulated expres-
sion in ﬁbroids, showed that 2 variant members of the
collagen gene family, COL6A3 and COL13A1, are associated
with the risk and tumor size in the EA and AA study
populations.
Of these, 3 are missense variants not previously impli-
cated in known collagen-related pathologies. Consistent
with UL being a common condition, 2 of these mutations,
c.9034G>C (p.Ala3012Pro) and c.6653C>T (p.Pro2218Leu)
in COL6A3, are frequently observed in worldwide populations
(19.7% and 6.5% on average in the 1,000 genome popula-
tions). However, we cannot assess whether these mutations
are functional and causally related to ULs. For these
hormone-dependent tumors, variations in the encoded factors
of the estrogen and insulin-like growth factor signaling likely
come into play to modify the risk for or size of ULs. The linked
INS and IGF-2 genes emerged as putative targets in the pre-
sent study, but only in the EA population, consistent with
published data (27, 28).
Furthermore, using a random selection of MALD SNPs
overlapping positional candidate regions and random
genomic regions, we show that ARHGAP26, also called
GRAF1, is another possible target in ULs because its product
regulates cell spreading (29), and the encoded variants may
affect the supramolecular structure of the extracellular ma-
trix. Possibly owing to the low SNP coverage (rs35294 was532the only typed SNP in this 459 Kb–long gene), the replication
of this association was not observed in the AA population.
The strongest association in the AA population was observed
with an intronic variant in MAN1C1. Likewise, the low SNP
coverage of this 169 Kb–long MAN1C1 gene may explain
the nonreplication of the results in the EA population. This
gene encodes Golgi human a 1,2-mannosidase IC, an enzyme
that plays an essential role in the maturation of N-glycans (a
review is available [30]).
Collectively, the results of the present study point to
altered regulation, maintenance, and/or renewal of the extra-
cellular matrix as potentially important etiologic processes in
the development of ﬁbroids. Dysregulation of these cellular
activities can be caused by changes in the amino acid struc-
ture of the encoded collagen molecules or by defective post-
translational modiﬁcation by mannosidases that potentially
prevent their proper transfer, folding, or degradation. Alter-
natively, aberrant methylation of collagen genes, including
COL6A3, has been implicated in the development of uterine
ﬁbroids (31). The strongest candidate genes identiﬁed in this
study may function in shared or interconnected cellular pro-
cesses dysregulated in ULs; further validation of these data
and analyses of gene-gene interactions with conﬁrmed can-
didates may provide clues.
The convergent view that encoded variants of collagen
genes or variants of their posttranslational products
may drive the pathogenesis of ﬁbroids is in line with the re-
ported gene-proﬁling data that emphasized the role of theVOL. 103 NO. 2 / FEBRUARY 2015
Fertility and Sterility®extracellular matrix, collagen structure, and transforming
growth factor beta in ﬁbroid formation (19). Moderate associ-
ations (.01<P>.05) of TGFBR2 (transforming growth factor,
beta receptor II gene) with risk and ﬁbroid size were observed
in both population groups (Supplemental Table 1).
None of the reported associations passed the Bonferroni-
corrected signiﬁcance thresholds; however, the most signiﬁ-
cant associations (MAN1C1, COL13A1, ARHGAP26, and
LIFR) have P values close to the threshold values. The border-
line statistical signiﬁcances of our data after correction for
multiple testing should be interpreted in the context of prior
and independent implications of the extracellular matrix
components, namely collagens, in the pathophysiology of ﬁ-
broids (19, 32), of the role of leukemia inhibitor factor (LIF) in
embryonic uterine development and of replications of several
gene associations in one or the other study population.
Here we reported association results from models in
which the controls were treated as the category with the
lowest level of the polytomous outcome. The rationale for
this design is that tumor sizes of <0.5 cm in diameter are un-
likely to be detected by the ultrasound method in studies of
this common condition that are prone to substantial misclas-
siﬁcations, especially in cross-sectional studies. In addition,
we tested the association with tumor size in case-only designs
and in race-stratiﬁed analysis and meta-analysis. These ana-
lyses led to ﬁndings similar to those reported here and addi-
tionally highlighted new candidate genes in meta-analyses
that were not observed in race-stratiﬁed analyses (Aissani B
et al., unpublished data).
The candidate 2q37 region that contains COL6A3 was
identiﬁed in independent linkage and admixture studies,
and was followed up in the present NIEHS study. However,
back validation of our results in the affected sister study
and the Black Women's Health Study has not yet been under-
taken. This step is important for the validation of our ﬁnding
for this gene, and the reﬁnement of the candidate gene list for
more focused follow-up sequencing and functional studies.
The present association data add to the growing and com-
plex picture of genetic susceptibility to ULs. Clear connec-
tions, if any are present, of the published gene-expression
proﬁling and the present data to the disease models that
implicate MED12 or FASN dysregulation in uterine ﬁbroids,
are yet to be established. Most of the identiﬁed candidate
genes affect both the risk and tumor size outcomes. This
observation supports a model for a continuous disease pheno-
type, possibly resulting from an inability to repair abnormally
accumulated collagen ﬁbers in the extracellular matrix.
Through our approach of selecting positional candidate genes
with regulated expression in ULs, we increased the chance of
identifying clinically relevant markers.
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Study Population and Quality Control
Except for a unique individual of European descent, typing
was achieved in the entire study population (n¼ 1,152), which
included subsets of 82 quality control (QC) samples and 25
Yoruban samples. The call rate was >98% in about 92% of
the sampled individuals; for analysis, we excluded 42 individ-
uals (4.0%) who had call rates of <90%. The overall concor-
dance rate between the duplicates was 99.6%, implying that
false ﬁndings resulting from typing errors were unlikely. The
yield was a total of 1,003 samples available for the analysis.
Discriminant analysis corrected the population inference for
several individuals who self-identiﬁed as ‘‘Other,’’ into either
the EA or the AA group (16). Sixteen individuals who self-
identiﬁed as AA, and 1 individual who self-identiﬁed as a
non-Hispanic EA, clustered more closely with the Yoruban
population. This observation prompted the exclusion of this
subset of 17 individuals, resulting in a total of 986 individuals
(525 AA, 391 EA, and 70 Other) available for analysis.VOL. 103 NO. 2 / FEBRUARY 2015 534.e1
SUPPLEMENTAL FIGURE 1
Quantile-quantile plots of the test statistic P value obtained using MALD and non-MALD SNPs in the NIEHS-UFS. MALD SNPs are a set of random
SNPs within and outside candidate chromosomal regions identiﬁed in independent and published linkage and admixture studies. Non-MALD SNPs
are positional SNPs selected frompositional candidate geneswith regulated expression in uterine ﬁbroids. Race-stratiﬁed plots are shown separately
for MALD and non-MALD SNPs for risk and for tumor size outcomes.
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SUPPLEMENTAL FIGURE 2
See Supplemental Figure 1 caption.
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See Supplemental Figure 1 caption.
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SUPPLEMENTAL FIGURE 4
See Supplemental Figure 1 caption.
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See Supplemental Figure 1 caption.
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See Supplemental Figure 1 caption.
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See Supplemental Figure 1 caption.
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See Supplemental Figure 1 caption.
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SUPPLEMENTAL FIGURE 9
Follow-up ﬁne mapping of candidate chromosomal regions for the risk of uterine ﬁbroids in the NIEHS study using selected SNPs. Manhattan plot
showing the statistical signiﬁcance (expressed as minus logarithm of P values) of the association of tagging SNPs with the risk of uterine ﬁbroids
(case and control study). The ﬁgure displays the results for tagging SNPs selected from positional (circles) and nonpositional (squares) candidate
genes with differential expression in ﬁbroids and matched myometria (P<.01). Filled and empty symbols indicate data obtained with the AA
and the EA study populations, respectively. Note that chromosomes are separated by vertical lines, and the location of the SNPs is drawn to the
chromosome scales, with the axis labels for the chromosome number shown in centromeric positions separating chromosome p and q arms.
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SUPPLEMENTAL FIGURE 10
Follow-up ﬁne mapping of candidate chromosomal regions for the risk of uterine ﬁbroids in the NIEHS study using random SNPs. Manhattan plot
showing the statistical signiﬁcance (expressed as minus logarithm of P values) for the associations between selected SNPs with the risk of uterine
ﬁbroids (case and control study). The ﬁgure displays the results for a random set ofMALD SNPs spanning candidate chromosomal regions (circles) or
random genomic regions (squares). Filled and empty symbols indicate data obtained with the AA and EA study populations, respectively. Note that
chromosomes are separated by vertical lines, and the location of the SNPs is drawn to the chromosome scale, with the axis label for the chromosome
number shown in the centromeric positions separating chromosome p and q arms.
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SUPPLEMENTAL FIGURE 11
Follow-up ﬁne mapping of candidate chromosomal regions for the growth of uterine ﬁbroids in the NIEHS study using selected SNPs. Manhattan
plot showing the statistical signiﬁcance (expressed as minus logarithm of P values) for the association of selected SNPs with the size of uterine
ﬁbroids (polytomous outcome: none, small, medium, and large ﬁbroids). The ﬁgure displays the results for tagging SNPs selected from
positional (circles) and nonpositional (squares) candidate genes with differential expression in ﬁbroids and matched myometria (P<.01). Filled
and empty symbols indicate data obtained with the AA and EA study populations, respectively. Note that chromosomes are separated by
vertical lines, and the location of the SNPs is drawn to the chromosome scale, with the axis label for the chromosome number shown in the
centromeric positions separating chromosome p and q arms.
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SUPPLEMENTAL FIGURE 12
Follow-up ﬁne mapping of candidate chromosomal regions for the growth of uterine ﬁbroids in the NIEHS study using random SNPs. Manhattan
plots showing the statistical signiﬁcance of the tests of association (expressed as minus logarithm of P values) of selected SNPs with the size of
uterine ﬁbroids (polytomous outcome: none, small, medium, and large ﬁbroids). The ﬁgure shows the association results for a random set of
MALD SNPs spanning candidate chromosomal regions (circles) or random genomic regions (squares). Filled and empty symbols indicate data
obtained with the AA and EA study populations, respectively. Note that chromosomes are separated by vertical lines, and the location of the
SNPs is drawn to the chromosome scale, with the axis labels for the chromosome number shown in the centromeric positions separating
chromosome p and q arms.
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